Tag:

Sanofi

Latest Headlines

Latest Headlines

Report: GSK, J&J, Merck and Sanofi have made mobile app breakthroughs

A report by Research2Guidance found that GlaxoSmithKline, Johnson & Johnson, Merck and Sanofi outperformed their peers in terms of apps downloaded.

Chris Viehbacher leaving Sanofi without a U.S.-style windfall

For the now-former chief of Sanofi, Chris Viehbacher, there's plenty of money for a cushion, but it won't be nearly as plump as the packages granted to his counterparts in the U.S.

Novo Nordisk quells diabetes pricing fears with 2015 growth forecast

Novo Nordisk has made diabetes-minded investors very happy today. Rather than following Sanofi's discouraging announcement of flat sales expectations in the field next year, the Danish drugmaker said it's expecting growth in the high single digits.

Sanofi will produce generics of 6 drugs in Dubai

Sanofi, which bought controlling interest in Dubai's Globalpharma in June, will kick off production there with generics of 6 of its drugs. Sanofi is now managing the facility.

Ex-Sanofi CEO Viehbacher in line for up to $7.8M cash payoff

For the now-former chief of Sanofi, Chris Viehbacher, there's plenty of money for a cushion, but it won't be nearly as plump as the packages granted to his counterparts in the U.S.

CEO-hunting Sanofi tried to tempt AstraZeneca's Soriot: Bloomberg

Bernstein analyst Tim Anderson figures Sanofi would do well to look outside the company for its new CEO, like AstraZeneca did with its new-ish chief, Pascal Soriot. Well, Sanofi had a more literal view: The French drugmaker has contacted Soriot himself.

Diabetes pricing war? Sanofi, Lilly and Novo each have their ideas

When Sanofi announced that its franchise would suffer next year because of U.S. payer contracts, the natural follow-up question was this: Does this mean a diabetes pricing war? If Sanofi had to boost its rebates to win coverage--which the company admits it did--then that means its rivals, including Eli Lilly and Novo Nordisk, have, too.

Possible threat to strong launch of Merial's anti-flea pill NexGard adds to Sanofi's woes

Sanofi's animal health division, Merial, provided a rare bright spot in the company's third-quarter earnings report--but it wasn't quite bright enough to save CEO Chris Viehbacher's job. On Wednesday, just after announcing so-so earnings that triggered a massive selloff of Sanofi's stock, the company's board said it has "decided unanimously to remove" Viehbacher.

Sanofi board ousts CEO, aiming for a more 'cooperative' chief

In a terse statement Wednesday morning, Sanofi's board said it had unanimously voted to fire Viehbacher, who has led the company since 2008.

Sanofi CEO Chris Viehbacher gets the boot: What happens next in R&D?

Chris Viehbacher took the helm of Sanofi with one clear message about the future: R&D at the Big Pharma had to undergo a radical restructuring. The lost decade in drug development following 2000 proved that Sanofi and others had to mend their ways, he said, forcing the company to reach outside the organization for innovation and shed the dead wood that had accumulated in its research ops.